Skip to content
Research Article Open access CC BY 4.0

Carcinosarcoma of Ovary, it’s Histopathological, Management and Prognostic Analysis with Review of Literature

Rohani Nayak, Tapan Kumar Sahoo

Journal of Cancer and Tumor International · pp. 1–10 · Published 15 Dec 2015

10.9734/JCTI/2016/22769

Abstract

Carcinosarcoma is a mixed malignant biphasic tumour representing a rare entity and comprises of both epithelial and mesenchymal components. Primary ovarian carcinosarcoma is a rare neoplasm with a number of cases reported in the literature in the hundreds. It accounts for less than 1% of all ovarian tumours. These tumours are usually diagnosed at older age and advanced stage. It has aggressive clinical behaviour and survival depends on stage at presentation. Radiological imagings cannot differentiate carcinosarcomas from other ovarian cancers. Diagnosis is based upon histological findings. Cytoreductive debulking surgery is a crucial part in the treatment of carcinosarcoma of ovary. The role of adjuvant chemotherapy regimen is still controversial. Combination chemotherapy with taxane and platinum based regimen or ifosfamide and platinum based regimen are considered as adjuvant treatment. Despite aggressive treatment modalities such as surgery and chemotherapy, the outcome is poor. Response to therapy and overall survival for carcinosarcoma are poor in comparison to that of epithelial ovarian malignancies. Due to rarity of the disease, such poor prognosis needs collaboration of studies with molecular analysis to obtain new therapeutic guidelines to improve survival of the patients.  

Carcinosarcoma chemotherapy cytoreductive surgery heterologous elements prognosis ovary

References (29)

  1. 1 Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study [DOI]
  2. 2 Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer [DOI]
  3. 3 Ovarian and Uterine Carcinosarcomas [DOI]
  4. 4 Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. [DOI]
  5. 5 Carcinosarcoma of the ovary [DOI]
  6. 6 Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (A Gynecologic Oncology Group Study) [DOI]
  7. 7 Carcinosarcomas (Malignant Mullerian Mixed Tumors) of the Uterus and Ovary: A Genetic Study With Special Reference to Histogenesis [DOI]
  8. 8 Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
  9. 9 Carcinosarcoma of the ovary—a case series [DOI]
  10. 10 Carcinosarcoma of the ovary: A case–control study [DOI]
  11. 11 Current management of ovarian carcinosarcoma [DOI]
  12. 12 Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: A SEER analysis [DOI]
  13. 13 Carcinosarcoma of the ovary treated with platinum and taxane: The memorial Sloan-Kettering Cancer Center experience [DOI]
  14. 14 Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study [DOI]
  15. 15 Mixed mesodermal tumor of the ovary: Analysis of prognostic factors in 31 cases [DOI]
  16. 16 The effect of epithelial and stromal tumor components on FIGO stages III and IV ovarian carcinosarcomas treated with primary surgery and chemotherapy [DOI]
  17. 17 A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: A gynecologic oncology group study [DOI]
  18. 18 Malignant mixed müllerian tumors of the ovary. Experience with surgical cytoreduction and combination chemotherapy [DOI]
  19. 19 Malignant mixed mullerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy [DOI]
  20. 20 Morphologic Prognostic Factors of Malignant Mixed Müllerian Tumors of the Ovary [DOI]
  21. 21 Malignant mixed mullerian tumour of the ovary: Prognostic factor and response of adjuvant platinum‐based chemotherapy [DOI]
  22. 22 Presence of a Sarcomatous Component Outside the Ovary Is an Adverse Prognostic Factor for Primary Ovarian Malignant Mixed Mesodermal/Mullerian Tumors [DOI]
  23. 23 Conventional Chemotherapy and Oncogenic Pathway Targeting in Ovarian Carcinosarcoma Using a Patient-Derived Tumorgraft [DOI]
  24. 24 Clinico-pathological spectrum of primary ovarian malignant mixed mullerian tumors (OMMMT) from a tertiary cancer institute: A series of 27 cases [DOI]
  25. 25 Malignant mixed mullerian tumors of the ovary: histopathologic and clinical review of 36 cases [DOI]
  26. 26 Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. [DOI]
  27. 27 Ovarian malignant mixed mullerian tumor with primitive neuroectodermal differentiation: Case report with review of the literature [DOI]
  28. 28 CARCINOSARCOMA OF OVARY AND ITS MANAGEMENT, A CASE REPORT AND REVIEW OF LITERATURE
  29. 29 Malignant Mixed Mesodermal Tumor of Ovary in Young Female: A Rare Case Report

Cited by 1

Spotlight on Carcinosarcoma of the Ovary: A Scoping Review

Martina Gauci, Jean Calleja-Agius · Acta Medica (Hradec Kralove, Czech Republic) · 2024

Related research

Article metrics

Real usage data collected on this platform.

52

Page views

0

PDF downloads

12

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.